	direct investment						Indirect																				
	i	→		j	i	→		q1	→		j		i	→		q2	→		j							
		deg	pij			deg	piq1		deg	pq1j		piq * pqj		deg	piq2		deg	pq2j		piq2 * pq2j		i – qn – j			
	IDOGEN AB	11	0.09	MENDUS AB	IDOGEN AB	11	0.09	APOTEK PR	2	0.50	MENDUS AB	0.045										....	0.019		
	IDOGEN AB	11	0.09	APOTEK PRODUKTION &	IDOGEN AB	11	0.09	MENDUS AB	2	0.50	APOTEK PRODUKTION & L	0.045										....	0.019		
	IDOGEN AB	11	0.09	CERENO SCIENTIFIC AB																		....	0.008		
	IDOGEN AB	11	0.09	UMECRINE COGNITION AB																		....	0.008		
	IDOGEN AB	11	0.09	XINTELA AB																		....	0.008		
Burt	IDOGEN AB	11	0.09	PCI BIOTECH HOLDING A	IDOGEN AB	11	0.09	ZICCUM AB	2	0.50	PCI BIOTECH HOLDING AS	0.045										....	0.019		
	IDOGEN AB	11	0.09	RECCURA THERAPEUTICS AS																		....	0.008		
	IDOGEN AB	11	0.09	ZICCUM AB	IDOGEN AB	11	0.09	PCI BIOTECH	2	0.50	ZICCUM AB	0.045										....	0.019		
	IDOGEN AB	11	0.09	BIOEXTRAX AB	IDOGEN AB	11	0.09	CYCLEZYME	2	0.50	BIOEXTRAX AB	0.045										....	0.019		
	IDOGEN AB	11	0.09	CYCLEZYME AB	IDOGEN AB	11	0.09	BIOEXTRAX	2	0.50	CYCLEZYME AB	0.045										....	0.019		
	IDOGEN AB	11	0.09	PHARMALUNDENSIS AB																		....	0.008		
									?			0.273										....	**0.153**		
																						....			
																						....			
	IDOGEN AB	11	0.09	MENDUS AB	IDOGEN AB	11	0.09	APOTEK PR	16	0.06	MENDUS AB	0.006										....	0.009		
	IDOGEN AB	11	0.09	APOTEK PRODUKTION &	IDOGEN AB	11	0.09	MENDUS AB	24	0.04	APOTEK PRODUKTION & L	0.004										....	0.009		
	IDOGEN AB	11	0.09	CERENO SCIENTIFIC AB																		....	0.008		
	IDOGEN AB	11	0.09	UMECRINE COGNITION AB																		....	0.008		
	IDOGEN AB	11	0.09	XINTELA AB																		....	0.008		
Igraph	IDOGEN AB	11	0.09	PCI BIOTECH HOLDING A	IDOGEN AB	11	0.09	ZICCUM AB	6	0.17	PCI BIOTECH HOLDING AS	0.015										....	0.011		
	IDOGEN AB	11	0.09	RECCURA THERAPEUTICS AS																		....	0.008		
	IDOGEN AB	11	0.09	ZICCUM AB	IDOGEN AB	11	0.09	PCI BIOTECH	8	0.13	ZICCUM AB	0.011										....	0.010		
	IDOGEN AB	11	0.09	BIOEXTRAX AB	IDOGEN AB	11	0.09	CYCLEZYME	2	0.50	BIOEXTRAX AB	0.045										....	0.019		
	IDOGEN AB	11	0.09	CYCLEZYME AB	IDOGEN AB	11	0.09	BIOEXTRAX	2	0.50	CYCLEZYME AB	0.045										....	0.019		
	IDOGEN AB	11	0.09	PHARMALUNDENSIS AB																		....	0.008		
																							0.119		

Burt defines dyadic constraint c_{ij} as

$$c_{ij} = \left(p_{ij} + \sum_{q \in N(i)-j} p_{iq} p_{qj} \right)^2 \quad (1)$$



$$c_i = \sum_{j \in N(i)} c_{ij}$$